Biopharmaceutical company focused on developing recombinant therapeutic proteins expressed through its proprietary plant cell-based protein expression system.
Protalix BioTherapeutics, Inc. is a pioneering biopharmaceutical firm dedicated to advancing recombinant therapeutic proteins using its innovative ProCellEx plant cell-based protein expression system. Headquartered in Hackensack, New Jersey, the company operates globally, including in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and beyond. Protalix BioTherapeutics is recognized for its groundbreaking product Elelyso, a treatment for Gaucher disease.
The company's robust pipeline features several promising candidates. Among them is PRX-102, nearing the final stages of clinical trials as a therapeutic protein for Fabry disease. Additionally, PRX-110, a proprietary plant cell-derived form of human deoxyribonuclease I, has completed phase IIa clinical trials aimed at addressing cystic fibrosis. Protalix BioTherapeutics also develops PRX-115, a plant cell-expressed PEGylated Uricase designed for treating gout, and PRX-119, a PEGylated recombinant human DNase I product candidate targeting diseases related to NETs (neutrophil extracellular traps).
In pursuit of its mission, Protalix BioTherapeutics collaborates extensively with strategic partners. These partnerships include alliances with pharmaceutical giants like Pfizer, Fundação Oswaldo Cruz (Fiocruz), and Chiesi Farmaceutici S.p.A. These collaborations underscore the company's commitment to leveraging cutting-edge biotechnological advancements to deliver innovative therapeutic solutions.
Founded in 1993, Protalix BioTherapeutics continues to push the boundaries of biopharmaceutical innovation. With a strong foundation in plant cell-based expression systems and a global presence, the company remains poised to revolutionize treatment options for rare and challenging diseases worldwide.